Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
… patients are at an increased risk of developing heart failure. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) could be a valuable treatment option. This study inves…
… include Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) or ivabradine and was restricted to HFrEF.We have here introduced the Blackpo…
… of Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i). Use of Ivabradine (if heart rate ≥70 bpm in sinus rhythm) and hydralazine–isosorb…
…the consolidation of four foundational pharmacological pillars: beta-blockers, renin-angiotensin system inhibitors or angiotensin receptor-ne…
… among the GLP-1RA group compared with the sulfonylureas group. GLP-1RA=glucagon-like peptide-1 receptor agonistsDiscussionIn this nati…
…cial in these patients. Remarkably, the benefits of GLP-1RA and SGLT2i are independent of type 2 diabetes status or baseline renal fun…
…ient, with ICERs generally below willingness-to-pay thresholds. Dapagliflozin was cost saving in type 2 diabetes (T2D) in the United Kingdom …
…all-cause mortality occurred in 551 out of 13,239 (4.2%) in the empagliflozin group and 6,589 out of 49,264 (13.4%) in the active control gro…
…stic accuracy of HFpEF Scores versus inclusion criteria used in sodium-glucose cotransporter-2 inhibitors (SGLT2i) trials, age-adjusted N-terminal pro B-type natriuretic…
…atrial myopathy. Our data indicate an anti-arrhythmic effect of SGLT2i, meriting investigation. This study provides insight into HF en…
…at the diagnosis of T2DM was high. Most prescriptions contained metformin. Monotherapy decreased in 2023–2024 compared with 2018–2022, wh…
…, 65% of patients were male. Median LVEF was 50% [IQR 41 – 56]. β-blockers were prescribed in 88.8% of patients, ARNI in 78.1%, MRAs in 45…